bioRxiv Science⌕ Search

bioRxiv · 10.64898/2026.10.19.760241

Functional heterogeneity, tumor vascularization, and the nonlinear dynamics of metastatic cancer treated by oncolytic viral therapy

Abstract

Oncolytic viral therapy (OVT) is an emerging cancer treatment where therapeutic viruses are injected into a patient. Models have been developed which describe the interactions of the virus, tumor and immune system through systems of nonlinear ordinary differential equations (ODEs). Some suggest that an initial phase of treatment with immunosuppressants could improve the efficacy of OVT by preventing the immune system from attacking the oncolytic viruses before they can infect many tumor cells. However, all such models have focused on a single, localized tumor. Here, we model a primary tumor and its continuous metastatic seeding of a secondary organ under simplifying assumptions about tumor vascularization. Bifurcation analysis and simulations reveal regions in parameter space for which immune modulation encourages distant metastasis, leading to the dangerous scenario where the elimination of a primary tumor creates the false impression of a good prognosis. We also suggest that vascular disrupting agents may be useful for treating small tumors while they may promote OVT resistance in larger tumors.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Evans, T. P., Martin, M.. 2026-10-20. Functional heterogeneity, tumor vascularization, and the nonlinear dynamics of metastatic cancer treated by oncolytic viral therapy. https://doi.org/10.64898/2026.10.19.760241

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Elevated polyadenylated histone gene transcription in human cancer

Histone production is tightly restricted to S-phase to prevent genomic instability, yet human cancers with an overabundance of RNA Polymerase II (RNAPII) at histone genes are associated with aggressive cancers. To better understand histone gene overexpression in cancer, we applied a quantitative PCR assay to measure total replication-coupled histone output across the histone gene clusters using cell line models. We observed pervasive accumulation of polyadenylated histone transcripts, supported by analysis of >1,400 RNA-sequencing datasets in human cancers, with more than 70% of patients showing tumor specific increases. This alternative processing preferentially enriches for histone H2B, which lacks replication independent variants, across >8,300 tumors comprising diverse cancer types and transcriptional subtypes. We also found that disruption of nuclear components required to maintain RNAPII levels at the histone genes increased polyadenylated histone transcripts. Our results suggest that S-phase-dependent histone genes are subject to unscheduled gap phase transcription in human cancer.

cancer biology↗

Developmental origins of thymic B-cell lymphomas

The thymus provides a specialized niche for lymphocyte differentiation, yet the developmental trajectories of its rare B-cell population and their relationship to thymic B-cell lymphomagenesis remain poorly understood. Here, we integrate single-cell multiomics and spatial profiling across human tissues to delineate a B-cell differentiation program selectively represented in the human thymus. This program links CCL17 and germinal center-like B-cell states along a trajectory distinct from canonical germinal center differentiation and can be recapitulated in vitro by signals operating in the thymic medulla. Extending this framework across human B-cell lymphomas, we identify an inherent malignant cell state in PMBCL that shares transcriptional and epigenetic features with CCL17 thymic B cells. This malignant state associates with early clonal positions in reconstructed B-cell receptor phylogenies and persists within tumor microenvironments distinct from the thymic niche. Together, these findings support a model in which thymus-specific B-cell differentiation programs are redeployed during thymic B-cell lymphomagenesis.

cancer biology↗

Live immunogenic melanoma cells generated by etoposide treatment upregulate B2M and lose tumor-forming potential

Cytotoxic chemotherapy has been the primary cancer treatment modality for decades, however, chemotherapy drugs do not selectively target cancer cells. These drugs are toxic to all proliferating cells including immune cells that constitute the host-defense system against pathogens and cancer cells. In an effort to develop non-toxic combinations of chemotherapy and immunotherapies for cancer, we previously reported in Sriram et al. 2021 that etoposide-treated B16 melanoma cells expressing ovalbumin, when co-cultured in vitro with dendritic cells and T-cells, enhance T-cell activation. The live fraction of melanoma cells after etoposide treatment was critical to promote T-cell activation as dead cells alone or in combination with cell-free supernatants were not effective. In this study, we show that the live fraction of etoposide-treated B16-Ova cells, which gain the ability to stimulate T-cells, are growth-arrested, but remain viable past the co-incubation period with dendritic cells and T-cells post etoposide washout. Furthermore, using a soft-agar colony-formation assay as a proxy for tumor-forming potential, we show that these live etoposide-treated B16-Ova cells have drastically reduced ability to form colonies displaying a near-complete loss of anchorage-independent growth. We also show that etoposide treatment upregulates the production of Beta-2-microglobulin (B2M), a subunit of Class I MHC. Intriguingly, we observed using immunofluorescence that the live etoposide-treated B16-Ova cells show enhanced intracellular perinuclear B2M accumulation but B2M surface staining, while detectable, is not enhanced by etoposide treatment. Furthermore, while the live etoposide-treated B16-Ova cells express Class I MHC protein, there is only a marginal drug treatment-induced increase observed in the expression levels by western blotting. Our results suggest that T-cell activation by live etoposide-treated B16-Ova cells is likely not driven by drug treatment-induced enhancement in cell surface levels of Class I MHC and point to other mechanisms.

cancer biology↗